SS

SS Innovations International, Inc.

SSIIHealthcareNASDAQ

Medical Devices · Last scanned Sep 7, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$42.5M
+105.7% YoY
Net Income
-$12.1M
+36.7% YoY
EBITDA
-$6.0M
+66.3% YoY
Free Cash Flow
-$3.9M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 RSI OversoldRSI 27.4, below 30, stock may be oversold
Aug 13 MACD Negative CrossoverHistogram -0.0200, negative momentum
About SS Innovations International, Inc.

SS Innovations International, Inc., together with its subsidiaries, operates as a commercial-stage surgical robotics company in India, Philippines, Indonesia, South America, Iraq, Cyprus, Oman,. The $683.3M market capitalization puts SSII squarely in small-cap range for its industry. It offers SSi Mantra, a surgical robotic system; and SSi Mudra, a range of stapling, energy, and core instrumentations for surgical systems.

Where SSII stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, SSII finished 16.67% below its 150-day moving average ($4.08) and 24.44% below its 200-day moving average ($4.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is SSII overbought or oversold?

At the September 3, 2026 close, SSII's RSI(14) was 27.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$683.3M
Fwd P/E-56.83
EPS$-0.06
Beta0.58
52W Change-44.5%
ROE-26.1%
Analysis

SS Innovations International, Inc. carries $17.9M in total debt against $13.6M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$3.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -26.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.4M (2022) to $42.5M (2025), reflecting a 2858% increase over the period.

The relatively low beta of 0.58 suggests SSII is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for SS Innovations International, Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms